Figure 7.

In vivo tumor targeting of HFn–ICG and ICG. In vivo targeting of HFn–ICG (a,c) and ICG (b,d) was evaluated in tumor-bearing mice, 6 h after I.V. administration by IVIS Lumina II and by KARL STORZ NIR/ICG endoscopic system. (e) Imaging analysis of data obtained by IVIS Lumina II allowed us to quantify the dye in the tumor area (black dotted ROI). Fluorescence was higher in HFn–ICG than in free ICG-treated mice, but the difference was not statistically significant (p-value = 0.1112). Color scale expressed as total radiant efficiency (×10⁸), n = 3.